Reported 7 days ago
The weight-loss drug market, projected to reach $150 billion annually, has caused significant volatility in pharmaceutical stocks, especially for companies like Eli Lilly and Amgen. Recent performance misses have led to dramatic market reactions, including a notable drop in Lilly's stock value by $127 billion in one day. Investors are highly focused on GLP-1 drug sales, and the market is prone to rapid sell-offs triggered by negative news. Consequently, both excitement and caution surround these companies as they navigate this volatile environment.
Source: YAHOO